Navigation Links
Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
Date:3/31/2009

, respiratory agents, antidiabetics and immunologicals. The state-of-the-art research and development facility at Cadila Pharmaceuticals is manned by more than three hundred and fifty scientists and engineers from various disciplines including biology, pharmacology, clinical research, chemistry, toxicology, phytochemistry and different disciplines of engineering. The company also participates in public-private partnerships for developing preventive and curative pharmaceutical and diagnostic products. Over the last decade Cadila Pharmaceuticals has focused on novel approaches to cancer management and is the first Indian company to get multiple investigational new drug applications (INDs) approved by U.S. Food and Drug Administration. The company has state-of-the-art manufacturing facilities conforming to the most stringent international norms at various locations in India and in Addis Ababa in Ethiopia.

Forward Looking Statement

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding the strategic partnership with Cadila, the establishment of a manufacturing facility in India and the development and commercialization of VLP vaccines in India, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to whether all regulatory hurdles in India for transferring the Novavax intellectual property to the joint venture in exchange for equity in the joint venture, and gaining approvals to manufacture and commercialize any product in India can be achieved; whether the joint venture will have sufficient f
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... (PRWEB) August 19, 2014 XenoTech ... fast and cost-effective metabolite production from bioactive small ... chemistry platform, the technology enables convenient and timely ... According to XenoTech’s Vice President of Commercial Operations, ... for assessing clinical risk can be measured directly ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics ... ICOTF), today reported results of its Oral Amphotericin ... HIV reservoirs.  The study, conducted by ImmuneCarta®, the ... in vitro effectiveness of Oral Amp B ... present in individuals despite intensive treatment with antiretroviral ...
(Date:8/18/2014)... Md. , Aug. 18, 2014 /PRNewswire/ ... maker of advanced consumer medical devices said ... was interviewed by CEOLIVE.TV as part ... The entire interview is available at ... Dr. Kotak explains to investors the unique ...
(Date:8/18/2014)... According to the new ... (Municipal Wastewater Treatment and Industrial Wastewater Treatment), By ... By Configuration (Internal/Submerged and External/Sidestream), and By Region-Trends ... market for membrane bioreactor systems is projected to ... CAGR of 15.28% between 2014 and 2019. ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... As part of the,"SCIENCEsuisse" project, swissinfo.ch is presenting ... of disciplines. The focus is on,Switzerland,s high international ... SRG SSR idee suisse initiative, in collaboration with,the ... to give readers an insight into what,scientists are ...
... Strains A & B In,15 Minutes, Each year ... ill with "the,flu." Misdiagnosis of the flu is common ... this, overuse and unnecessary,use of antibiotics may be a ... This flu season, a new rapid flu test can ...
... Nov. 11 PointCross Inc., responding to ... Pharmaceuticals R&D industries, has released,a software catalyst ... business and technical solutions with extreme speed ... leading collaboration platform for,enterprise users. Larger global ...
Cached Biology Technology:25 Short Films About Top-Level Research on swissinfo.ch 2MultiVu Video Feed: New Rapid Test to Diagnose Flu May Help With Upcoming Flu Season 2PointCross Releases Catalyst for Building Business-Ready SharePoint Solutions in 1/10th the Time 2
(Date:8/19/2014)... scientists have identified a biomarker strongly associated with ... is resistant to many types of chemotherapy. The ... target for new therapeutics designed to treat this ... data taken from The Cancer Genome Atlas, molecular ... used powerful computational and bioinformatics techniques to detect ...
(Date:8/19/2014)... during warm phases and became extinct during cold phases, ... link between marine crocodilian diversity and the evolution of ... million years. , The research, led by Dr ... formerly from the University of Bristol, UK is published ... are ,cold-blooded, animals that mainly live in fresh waters ...
(Date:8/19/2014)... Anyone who has ever had a glass of fizzy ... the air. But in a finding with wide industrial ... push some particles down into the liquid as well. ... aerosol droplets, so we were surprised, and fascinated, to ... the same process injected tiny oil droplets into the ...
Breaking Biology News(10 mins):Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3Evolution of marine crocodilians constrained by ocean temperatures 2Bubbling down: Discovery suggests surprising uses for common bubbles 2Bubbling down: Discovery suggests surprising uses for common bubbles 3
... psychological society in the world, will grant its ... to Psychology" to Dr Friederike Range of the ... Medicine, Vienna (Vetmeduni Vienna). The award is recognition ... will be made in August 2012 at a ...
... of rare, endemic species in the Central Andes remain ... climate change, according to a Duke University-led international study. ... particularly vulnerable to changes in the environment or climate. ... percent of the areas with high numbers of these ...
... New York, NY (January 26, 2012) Researchers at the ... variation that raises the risk of developing serious necrotic jaw ... of osteoclastic inhibitors. The discovery paves the way for a ... drugs. The study appears in the online version of the ...
Cached Biology News:Dancing with wolves -- prestigious award goes to a scientist at the Vetmeduni Vienna 280 percent of 'irreplaceable' habitats in Andes unprotected 2Study pinpoints genetic variation that raises a risk linked to bisphosphonates 2Study pinpoints genetic variation that raises a risk linked to bisphosphonates 3
... Virgin, optically clear polystyrene with frosted ... coordinates for cell counting. 100% integrity ... a new product number, created to ... showing no availability yet, please order ...
... surface is produced by a patented microwave ... giving more consistent, even cell attachment, increased ... attachment and growth uunder difficult conditions, including ... may provide a more ecominic alternative to ...
... system, 100-240 V, uses xMAP technology for ... proteins and peptides in one microplate well. ... to 100 color-coded bead sets, each of ... reactant (enzyme substrates, receptors, antigens, or antibodies) ...
...
Biology Products: